PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting

City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting
2024-09-30
(Press-News.org) LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, is part of today’s press conference program at the American Society for Radiation Oncology (ASTRO) Annual Meeting, where a renowned City of Hope radiation oncologist will present phase 3 clinical trial data showing that people with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival.

“The introduction of immunotherapy marked the first significant breakthrough in treating small cell lung cancer treatment in decades. Now, we see that if you give immunotherapy concurrently with chemoradiation, it does not yield the same survival benefit as it does when we add it after standard treatment,” said lead author Kristin Higgins, M.D., a radiation oncologist, clinical professor and chief clinical officer at City of Hope Cancer Center Atlanta.  

Dr. Higgins is presenting the late-breaking abstract at a 10 a.m. ET press conference today in room 103A of the Walter E. Washington Convention Center in Washington, D.C.; the scientific plenary will take place at 2:10 p.m. ET in Ballroom A/B/C.

ASTRO is the world’s largest radiation oncology society, with more than 10,000 members. Radiation therapy contributes to 40% of global cancer cures, and more than 1 million Americans receive radiation treatments for cancer each year.

Lung cancer is the leading cause of cancer deaths in the U.S. An aggressive form of the disease is small cell lung cancer, which accounts for 10-15% of all lung cancers. Standard treatment for patients with limited-stage disease that has not spread outside the chest and is potentially curable includes concurrent radiation therapy and chemotherapy. While treatments can be effective initially, the cancer often recurs and options for additional treatment have historically been limited.  

Dr. Higgins and her colleagues randomized 544 patients at centers across the U.S. (n=500) and Japan (n=44) to receive standard chemoradiation with or without atezolizumab immunotherapy. All patients received radiation therapy either twice daily or once daily as well as four cycles of concurrent chemotherapy. For patients on the experimental arm, atezolizumab was also given every three weeks beginning at the start of radiation, for a maximum of one year.

Contrary to expectations, concurrent treatment with atezolizumab and chemoradiation did not improve survival rates compared to standard care. The lack of survival benefit when giving immunotherapy together with chemoradiation, rather than after radiation is completed, indicates that the activity of this type of immunotherapy is reduced when given simultaneously with thoracic radiation, likely due the inherent immunosuppressive effects of radiation, Dr. Higgins explained. 

“We know that radiation suppresses the immune system to a certain degree in the immediate sense, and immunotherapy relies on the immune system to be effective,” she said. “Adding these drugs after you give radiation can make the immunotherapy more potent, but you have to allow the immune system time to recover to really see the two work well together.”

There was a benefit to giving radiation twice daily over giving it once daily, regardless of study arm. In both groups, patients treated twice daily lived longer on average; median overall survival for those treated twice daily was 35.4 months, compared to 28.3 months for people treated once per day.

“Sometimes, if you give too much therapy at the same time, it actually yields worse outcomes. And this trial demonstrated that. But at the same time, we did see that changing the way you give radiation can help,” Dr. Higgins said, noting that City of Hope continues to be at the forefront of a powerful form of immunotherapy known as chimeric antigen receptor (CAR) T cell therapy. City of Hope researchers are among the scientists working to develop and test new lung cancer immunotherapy treatments.

Other world-renowned City of Hope physicians and researchers also will present new data and offer expert perspectives on leading-edge cancer research and treatments in development.

 

Is biology-guided radiotherapy an option for people with prostate cancer?

Presentation time and location: Monday, Sept. 30, from 3:50 to 4 p.m. ET in Room 145

City of Hope was the first in Southern California and among the first in the nation to adopt a type of biology-guided radiotherapy called SCINTIX therapy that later in 2023 was cleared by the U.S. Food and Drug Administration. This study, led by Chunhui Han, Ph.D., City of Hope clinical professor of radiation oncology, included prostate cancer patients and resulted in the development of a comprehensive set of screening criteria to identify people who would benefit from this leading-edge, personalized radiation oncology treatment. City of Hope aims to develop efficient protocols so that other institutions one day can also implement the SCINTIX therapy on the RefleXion X1.

 

Phase 2 trial with leukemia patients could lead to radiotherapy that attempts to bypass harm to organs

Presentation time and location: Monday, Sept. 30, from 5:10 to 5:20 p.m. ET in Room 144

In a phase 2 trial noted as the largest prospective study using total marrow and lymphoid irradiation (TMLI), Jeffrey Wong, M.D., City of Hope professor of radiation oncology, Anthony Stein, M.D., and colleagues treated 74 patients with either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) with TMLI, which delivers targeted radiation to bone marrow while reducing negative impact to organs. The team developed a regimen that could be an effective hematopoietic cell transplant option for AML and ALL patients with recurrent cancer or disease that has become resistant to treatment. The regimen is currently under evaluation as a potential replacement for standard total body irradiation conditioning in patients with AML who are in complete remission. City of Hope’s bone marrow and blood stem cell transplant program is the largest in the country; its doctors have performed nearly 20,000 transplants to date.

 

Study evaluating effectiveness of pre-transplant radiotherapy that limits toxicity to organs  

Presentation time and location: Tuesday, Oct. 1, from 1:25 to 1:35 p.m. ET in Room 144 

Colton Ladbury, M.D., City of Hope assistant professor of radiation oncology, led the largest study to date reporting long-term toxicities resulting from total marrow irradiation (TMI) and total marrow and lymphoid irradiation (TMLI), both of which are used to prepare patients for a stem cell transplant. Some 302 patients with multiple myeloma or acute leukemia were followed for up to eight years with median follow-up of 6.3 years in living patients. They found that TMI/TMLI is associated with lower rates of pulmonary toxicity, renal toxicity and hypothyroidism compared with historical cohorts treated with conventional total body irradiation.  

Dr. Ladbury is one of 12 residents in the world to receive an ASTRO recognition award for his quick pitch oral. The award is designed to highlight excellence among peers at the largest annual meeting of radiation oncologists from around the globe.

 

A potentially better way to deliver radiotherapy and chemotherapy to people with lung cancer

Presentation time and location: Tuesday, Oct. 1, from 1:25 to 1:35 p.m. ET in Room 147

In an early-phase trial, researchers led by Percy Lee, M.D., City of Hope professor of radiation oncology, found that it is safe and effective to treat patients with locally advanced, inoperable non-small cell lung cancer using chemoradiation via a dose-escalated adaptive stereotactic ablative radiotherapy boost in 15 sessions of radiation instead of the standard 30 sessions as they also receive chemotherapy.

 

Using AI to evaluate immune system response

Presentation time and location: Tuesday, Oct. 1, from 1:25 to 1:35 p.m. ET in Room 152

Immuno-positron emission tomography (ImmunoPET) allows for spatial evaluation of white blood cell distributions. William Tyler Watkins, Ph.D., physicist and City of Hope associate clinical professor, led a research team that leveraged artificial intelligence (AI) to segment the human body and evaluate CD8+ T cell concentrations before and after radiation therapy. The model was validated using data from five patients in an ongoing clinical trial and identifies varying patient-specific immune system response following radiation treatment.

 

Novel theranostic PET imaging agent for patients with advanced rectal cancer

Presentation time and location: Tuesday, Oct. 1, from 5:15 to 5:25 p.m. ET in Room 152

In an ongoing pilot study, Jeffrey Wong, M.D., City of Hope professor of radiation oncology, and colleagues found that a radioactive molecule attached to a monoclonal antibody (Cu-64-Anti-CEA M5A) shows promise as a theranostic — therapy plus diagnostic — tool that allows experts to identify disease sites in patients with rectal cancer. It also shows promise as a way to assess response to chemotherapy and radiotherapy received before cancer treatment, such as surgery. More research is needed to fully understand this therapeutic’s disease targeting and efficacy capabilities.

 

The below oral presentations have already been presented.

 

A promising treatment regimen for prostate cancer patients

Presentation time and location: Sunday, Sept. 29, from 8:30 to 8:40 a.m. ET in Room 207B

Early data from an ongoing phase 2 trial led by Savita Dandapani, M.D., Ph.D., City of Hope associate professor of radiation oncology, suggests that a promising treatment regimen for patients with metastatic castration-sensitive prostate cancer is radium 223 dichloride (Ra-223) combined with stereotactic body radiation therapy delivered to tumors that have spread to bone. The treatment plan should include 36 weeks of androgen deprivation therapy combined with the radiation. This is an early trial to show that the use of systemic radiation (radiopharmaceuticals) with stereotactic body radiation treatment may help prevent progression of micrometastases.

 

A new way to determine the strength of phase 3 cancer clinical trials

Presentation time and location: Sunday, Sept. 29, from 5:05 to 5:15 p.m. ET in Room 207B

A team of researchers led by Yufei Liu, M.D., Ph.D., City of Hope assistant clinical professor of radiation oncology, developed a benchmark to assess the strength of phase 3 clinical trials. They evaluated a database of 332 phase 3 oncology trials and found that targeted therapy trials, trials with progression-free survival as a final endpoint and positive trials tend to have the most robust, reproducible data. More work needs to be done to validate the developed benchmark, which could then be leveraged to design better clinical trials.

 

# # #

 

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.

END


[Attachments] See images for this press release:
City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting

ELSE PRESS RELEASES FROM THIS DATE:

A new and unique fusion reactor comes together with PPPL's contributions

A new and unique fusion reactor comes together with PPPLs contributions
2024-09-30
Like atoms coming together to release their power, fusion researchers worldwide are joining forces to solve the world’s energy crisis. Harnessing the power of fusing plasma as a reliable energy source for the power grid is no easy task, requiring global contributions. The Princeton Plasma Physics Laboratory (PPPL) — a U.S. national laboratory funded by the Department of Energy (DOE) — is leading several efforts on this front, including collaborating on the design and development of a new fusion device at the University of Seville in Spain. The SMall Aspect Ratio Tokamak (SMART) strongly ...

Reduced risk of serious cardiovascular disease after COVID vaccination

Reduced risk of serious cardiovascular disease after COVID vaccination
2024-09-30
People who have been fully vaccinated against COVID-19 have a significantly lower risk of developing more severe cardiovascular conditions linked to COVID-19 infection, according to a nationwide study at the University of Gothenburg. At the same time, some cardiovascular effects are seen after individual doses of the vaccine. The COVID-19 vaccine aims to reduce complications and overall mortality from the disease. At the same time, some cardiovascular effects have been seen after individual doses of the vaccine. A rare acute side effect is inflammation of the cardiac muscle or the pericardium in young men following mRNA vaccination. In terms of other cardiovascular ...

New laser-based headset can measure blood flow, assess risk of stroke

New laser-based headset can measure blood flow, assess risk of stroke
2024-09-30
When physicians want to know more about a patient’s risk of cardiovascular disease, they can order a cardiac stress test. But when it comes to risk of stroke, there is no equivalent scalable and cost-effective test of the brain’s function to help physicians counsel patients on their potential risk. A questionnaire that asks patients about contributing risk factors is currently the best tool for estimating such risk.   Now a team of engineers and scientists from Caltech and the Keck School ...

Researchers close in on understanding possible cause of Alzheimer’s disease

Researchers close in on understanding possible cause of Alzheimer’s disease
2024-09-30
CLEVELAND—With a four-year, $3.3 million grant from the National Institutes of Health (NIH), researchers from Case Western Reserve University will study whether certain brain proteins may play a role in the development of Alzheimer’s disease. Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills. According to the Alzheimer’s Association, nearly 7 million Americans 65 and older are living with the disease and there are more deaths from Alzheimer’s than breast and prostate cancer combined. Previous research has ...

New synthesis strategy could speed up PFAS decontamination

New synthesis strategy could speed up PFAS decontamination
2024-09-30
HOUSTON – (Sept. 30, 2024) – Rice University engineers have developed an innovative way to make covalent organic frameworks (COFs), special materials that can be used to trap gases, filter water and speed up chemical reactions. COFs have the potential to address significant environmental challenges, including energy storage and pollution control. An example of that is their potential use in the decontamination of “forever chemicals” or per- and polyfluoroalkyl substances (PFAS). Rice chemical engineer Rafael Verduzco and his team have described a new way to synthesize high-quality ...

COVID-19 linked to increased risk of acute kidney disorders: New study reveals time-varying effects

COVID-19 linked to increased risk of acute kidney disorders: New study reveals time-varying effects
2024-09-30
Researchers from West China Hospital, Sichuan University, have conducted a study revealing a significant association between COVID-19 and acute kidney disorders (AKD), including acute kidney injury (AKI), that varies over time. The study, led by Dr. Li Chunyang and Dr. Zeng Xiaoxi from the West China Biomedical Big Data Center, was recently published in the journal Health Data Science. COVID-19, known for its impact on the respiratory system, also affects other organs, including the kidneys. The study aimed to investigate the time-dependent effects of COVID-19 on acute kidney disorders. Using data from the ...

Medical imaging breakthrough could transform cancer and arthritis diagnosis

Medical imaging breakthrough could transform cancer and arthritis diagnosis
2024-09-30
A new hand-held scanner developed by UCL researchers can generate highly detailed 3D photoacoustic images in just seconds, paving the way for their use in a clinical setting for the first time and offering the potential for earlier disease diagnosis. In the study, published in Nature Biomedical Engineering, the team show their technology can deliver photoacoustic tomography (PAT) imaging scans to doctors in real time, providing them with accurate and intricate images of blood vessels, helping inform patient care. Photoacoustic ...

Genetic link between bipolar disorder and epilepsy unveiled in groundbreaking study

Genetic link between bipolar disorder and epilepsy unveiled in groundbreaking study
2024-09-30
Kunming, China - A team of researchers from the Chinese Academy of Sciences has uncovered compelling evidence of a genetic link between bipolar disorder type I (BD-I) and epilepsy, potentially revolutionizing our understanding of these complex neuropsychiatric conditions. The study, published in Genomic Psychiatry on September 30, 2024, reveals shared genetic variants and a causal relationship between the two disorders, opening new avenues for research and treatment. Led by Dr. Ming Li from the Kunming ...

Social networks help people resolve welfare problems - but only sometimes, new research finds

2024-09-30
Lead researcher Dr Sarah Nason, from Bangor University’s School of History, Law and Social Sciences explained: “Debt, benefits, special educational needs, healthcare issues, these are everyday problems that many of us face, and it’s only natural to turn to people you know and trust for help and advice. However, we found that having to talk to more people or support services was an indicator that the problem was more complex and difficult to resolve.” The team studied four distinct areas across England and Wales: Bryngwran, a village on Anglesey in North Wales; Deeplish, a district of Rochdale in Greater ...

Honey, I shrunk the city: What should declining Japanese cities do?

Honey, I shrunk the city: What should declining Japanese cities do?
2024-09-30
Aging societies and population decline have been on the rise globally, but in Japan, the situation has exasperated tenfold. A staggering 36.21 million people, or 28.9% of the populace, are 65 and over. Further, 74.6% of Japan’s 1,747 cities are categorized as shrinking, with urban policies struggling to keep up with the decline. However, the factors that correlate with population changes in cities of varying sizes have not been clarified. Dr. Haruka Kato, a junior associate professor at Osaka Metropolitan University, ...

LAST 30 PRESS RELEASES:

Workforce diversity is key to advancing One Health

Genome Research publishes a special issue on innovations in computational biology

A quick and easy way to produce anode materials for sodium-ion batteries using microwaves

‘Inside-out’ galaxy growth observed in the early universe

Protein blocking bone development could hold clues for future osteoporosis treatment

A new method makes high-resolution imaging more accessible

Tiny magnetic discs offer remote brain stimulation without transgenes

Illuminating quantum magnets: Light unveils magnetic domains

Different types of teenage friendships critical to wellbeing as we age, scientists find

Hawaii distillery project wins funding from Scottish brewing and distilling award

Trinity researchers find ‘natural killer’ cells that live in the lung are ready for a sugar rush

$7 Million from ARPA-H to tackle lung infections through innovative probiotic treatment

Breakdancers may risk ‘headspin hole’ caused by repetitive headspins, doctors warn

Don’t rely on AI chatbots for accurate, safe drug information, patients warned

Nearly $10M investment will expand and enhance stroke care in Minnesota, South Dakota

Former Georgia, Miami coach Mark Richt named 2025 Paul “Bear” Bryant Heart of a Champion

$8.1M grant will allow researchers to study the role of skeletal stem cells in craniofacial bone diseases and deformities

Northwestern to promote toddler mental health with $11.7 million NIMH grant

A new study finds that even positive third-party ratings can have negative effects

Optimizing inhibitors that fight antibiotic resistance

New Lancet Commission calls for urgent action on self-harm across the world

American Meteorological Society launches free content for weather enthusiasts with “Weather Band”

Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy

How your skin tone could affect your meds

NEC Society, Cincinnati Children's, and UNC Children’s announce NEC Symposium in Chicago

Extreme heat may substantially raise mortality risk for people experiencing homelessness

UTA professor earns NSF grants to study human-computer interaction

How playing songs to Darwin’s finches helped UMass Amherst biologists confirm link between environment and the emergence of new species

A holy grail found for catalytic alkane activation

Galápagos finches could be singing a different song after repeated drought—one that leads to speciation

[Press-News.org] City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting